Aesthetic Plastic Surgery

, Volume 34, Issue 1, pp 65–68 | Cite as

Is Breast Augmentation Using Hyaluronic Acid Safe?

  • Micheal J. McCleaveEmail author


Macrolane™, a compound composed of hyaluronic acid, is the newest product to be marketed for breast augmentation. Like many previous breast augmentation products, Macrolane has been authorised for use with very little published scientific data on its safety and efficacy in breast augmentation. This article reviews the evidence available on the safety of using hyaluronic acid and raises concerns with regard to its use as a product for breast augmentation, the technique recommended for its use, and the authorisation process for new implantable medical devices. It is strongly recommended that clinicians review the lack of data on Macrolane before offering it as a treatment option to patients.


Breast augmentation Hyaluronic acid Implants Injectable fillers Breast Breast cancer 


  1. 1.
    Bondurant S, Ernster V, Herdman R (eds) (1999) Committee on the Safety of Silicone Breast Implants. Institute of Medicine, Washington, DCGoogle Scholar
  2. 2.
    Fumihiko I, Toshiya H, Kazuaki S (2006) Hyaluronic acid breast augmentation. Jpn J Plast Reconstr Surg 49(12):1335–1341Google Scholar
  3. 3.
    Heden P, Olenius M (2008) Stabilised hyaluronic acid-based gel of non-animal origin, a promising new development for breast enhancement, unpublished pilot study provided by Q-Med, Uppsala, SwedenGoogle Scholar
  4. 4.
    Tengvar M, Heden P, Olenius M (2008) Breast augmentation with stabilised hyaluronic acid-based gel of non-animal origin: visualisation of tissue behind the implants, pilot study provided by Q-Med, Uppsala, Sweden, poster presented at IMCAS, Paris, 2008Google Scholar
  5. 5.
    Heden P, Sellman G, von Wachenfeldt M, Olenius M, Fagrell D (2009) Body shaping and volume restoration: the role of hyaluronic acid. Aesthetic Plast Surg 33:274–282CrossRefPubMedGoogle Scholar
  6. 6.
    Wong CH, Samuel M, Tan BK, Song C (2009) Capsular contracture in subglandular breast augmentation with textured versus smooth breast implants: a systematic review. Plast Reconstr Surg 118(5):1224–1236CrossRefGoogle Scholar
  7. 7.
    Gotte M, Yip GW (2006) Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66:10233–10237CrossRefPubMedGoogle Scholar
  8. 8.
    Marchetti D, Reiland J, Erwin B, Roy M (2003) Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer 104:167–174CrossRefPubMedGoogle Scholar
  9. 9.
    Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4:528–539CrossRefPubMedGoogle Scholar
  10. 10.
    Afify A, McNiel MA, Braggin J, Bailey H, Paulino AF (2008) Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast. Appl Immunohistochem Mol Morphol 16(2):121–127CrossRefPubMedGoogle Scholar
  11. 11.
    Wernicke M, Pineiro LC, Caramutti D, Dorn VG, Raffo MM, Guixa HG, Telenta M, Morandi AA (2003) Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan. Mod Pathol 16:99–107CrossRefPubMedGoogle Scholar
  12. 12.
    Delpech B, Chevallier B, Reinhardt N, Julien JP, Duval C, Maingonnat C, Bastit P, Asselain B (1990) Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int J Cancer 46:388–390CrossRefPubMedGoogle Scholar
  13. 13.
    Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, Hirvikoski P, Eskelinen M, Kosma VM (2000) Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156:529–536PubMedGoogle Scholar
  14. 14.
    Kazachtov E, Fridman A, Friss S (1998) Granulomatous pleurisy after mammoplasty induced by polyacrylamide. Arkh Patol 60(3):58–61Google Scholar
  15. 15.
    Lui CY, Ho CM, Iu PP, Cheung WY, Lam HS, Cheng MS, Liu HL (2008) Evaluation of MRI findings after polyacrylamide gel injection for breast augmentation. Am J Roentgenol 191(3):677–688CrossRefGoogle Scholar
  16. 16.
    Alazemi S, Suarez MM, Baier HJ (2008) Direct migration of liquid silicone oil to the mediastinum. Am J Med 121(2):e3–e4CrossRefPubMedGoogle Scholar
  17. 17.
    Investigational Device Exemption Staff (1998) Guidance on IDE Policies and Procedures. Office of Device Evaluation, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Rockville, MDGoogle Scholar
  18. 18.
    Kirkpatrick WN, Jones BM (2002) The history of Trilucent implants, and a chemical analysis of the triglyceride filler in 51 consecutively removed Trilucent breast prostheses. Br J Plast Surg 55(6):479–489CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC and International Society of Aesthetic Plastic Surgery 2009

Authors and Affiliations

  1. 1.Department of Plastic & Reconstructive SurgeryThe Royal Adelaide HospitalAdelaideAustralia

Personalised recommendations